| Literature DB >> 27017483 |
Alexander J Millman1, Lyn Finelli2, Anna M Bramley2, Georgina Peacock3, Derek J Williams4, Sandra R Arnold5, Carlos G Grijalva4, Evan J Anderson6, Jonathan A McCullers7, Krow Ampofo8, Andrew T Pavia8, Kathryn M Edwards4, Seema Jain2.
Abstract
OBJECTIVE: To describe and compare the clinical characteristics, outcomes, and etiology of pneumonia among children hospitalized with community-acquired pneumonia (CAP) with neurologic disorders, non-neurologic underlying conditions, and no underlying conditions. STUDYEntities:
Keywords: Community-acquired pneumonia; neurological disorders
Mesh:
Year: 2016 PMID: 27017483 PMCID: PMC4897771 DOI: 10.1016/j.jpeds.2016.02.049
Source DB: PubMed Journal: J Pediatr ISSN: 0022-3476 Impact factor: 4.406
Neurologic disorders among children hospitalized with CAP (n = 280)
| Neurologic disorders | No. (%) |
|---|---|
| Epilepsy | 121 (43.2) |
| Down syndrome | 75 (26.8) |
| Cerebral palsy | 57 (20.4) |
| Developmental delay | 43 (15.4) |
| Chromosomal abnormalities | 34 (12.1) |
| Spinal cord injury or abnormality | 21 (7.5) |
| Other neurologic disorders | 75 (26.8) |
| Hydrocephalus | 10 (13.3) |
| Hypotonia | 7 (9.3) |
| Muscular dystrophy | 6 (8.0) |
| Microcephaly | 5 (6.7) |
| Periventricular leukomalacia | 5 (6.7) |
| Metabolic disorders | 4 (5.3) |
| Agenesis of the corpus callosum | 4 (5.3) |
| Ischemic encephalopathy | 4 (5.3) |
| Spinal muscular atrophy type 1 and 2 | 4 (5.3) |
| Neurofibromatosis | 4 (5.3) |
| Static encephalopathy | 4 (5.3) |
| Autism | 3 (4.0) |
| Smith-Magenis syndrome | 3 (4.0) |
| Spastic quadriplegia | 3 (4.0) |
| Intraventricular hemorrhage | 2 (2.7) |
| Holoprosencephaly | 2 (2.7) |
| Chiari malformation | 2 (2.7) |
| Fetal alcohol syndrome | 1 (1.3) |
| Ganglioglioma | 1 (1.3) |
| Langerhans cells histiocytosis CNS disease | 1 (1.3) |
| Myasthenia gravis | 1 (1.3) |
| Motor neuron disease | 1 (1.3) |
| Craniosynostosis | 1 (1.3) |
CNS, central nervous system.
Disorders are not mutually exclusive, and children may have more than 1 neurologic disorder.
Excluding Down syndrome.
Characteristics of children hospitalized with CAP with and without neurologic disorders
| Characteristics | Group 1 | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Any neurologic disorder (n = 280) No. (%) | Non-neurologic underlying condition (n = 934) No. (%) | No underlying condition (n = 1144) No. (%) | Group 1 vs 2 | Group 1 vs 3 | |
| Male | 160 (57.1) | 524 (56.1) | 607 (53.1) | .76 | .22 |
| Race/ethnicity | |||||
| Non-Hispanic white | 137 (48.9) | 314 (33.6) | 488 (42.7) | <.01 | .06 |
| Non-Hispanic black | 66 (23.6) | 420 (45.0) | 295 (25.8) | <.01 | .45 |
| Hispanic | 62 (22.1) | 132 (14.1) | 258 (22.6) | <.01 | .88 |
| Other | 15 (5.4) | 68 (7.3) | 103 (9.0) | .26 | .05 |
| Age groups | |||||
| <2 y | 79 (28.2) | 389 (41.7) | 587 (51.3) | <.01 | <.01 |
| 2-4 y | 72 (25.7) | 246 (26.3) | 277 (24.2) | .84 | .60 |
| 5-17 y | 129 (46.1) | 299 (32.0) | 280 (24.5) | <.01 | <.01 |
| Insurance status | |||||
| Public | 177 (63.2) | 637 (68.2) | 654 (57.2) | .12 | .07 |
| Parent's education | |||||
| Some college or more | 179 (63.9) | 557 (59.6) | 676 (59.1) | .20 | .14 |
| Non-neurologic underlying condition | |||||
| Any non-neurologic underlying condition | 146 (52.1) | 934 (100) | NA | <.01 | NA |
| Congenital heart disease | 85 (30.4) | 87 (9.3) | NA | <.01 | NA |
| Asthma/RAD | 83 (29.6) | 696 (74.5) | NA | <.01 | NA |
| Chronic lung disease | 35 (12.5) | 59 (6.3) | NA | <.01 | NA |
| Preterm birth (<37 wk) | 26/79 (32.9) | 192/389 (49.4) | NA | <.01 | NA |
| Immunosuppressive condition | 12 (4.3) | 27 (2.9) | NA | .25 | NA |
| Other conditions | 14 (5.0) | 43 (4.6) | NA | .78 | NA |
| Vaccination receipt status | |||||
| | 183/213 (85.9) | 543/631 (86.1) | 534/625 (85.4) | .96 | .86 |
| Pneumococcal vaccine | 142/167 (85.0) | 487/577 (84.4) | 462/577 (80.1) | .72 | .71 |
| Influenza vaccine | 111/266 (41.7) | 230/844 (27.3) | 271/943 (28.7) | <.01 | <.01 |
| Social factors | |||||
| Lives in household with smoker | 81/278 (29.1) | 361/929 (38.9) | 388/1137 (34.1) | <.01 | .11 |
| Daycare attendance | 41/202 (20.3) | 253/757 (33.4) | 287/961 (29.9) | <.01 | <.01 |
| Reported symptoms | |||||
| Cough | 255 (91.1) | 898 (96.2) | 1077 (94.1) | <.01 | .06 |
| Fever | 251 (89.6) | 851 (91.1) | 1053 (92.1) | .46 | .19 |
| Shortness of breath | 197 (70.4) | 710 (76.0) | 750 (65.6) | .06 | .13 |
| Vomiting/nausea | 114 (40.7) | 518 (55.5) | 651 (56.9) | <.01 | <.01 |
| Diarrhea | 64 (22.9) | 253 (27.1) | 401 (35.1) | .16 | <.01 |
| Seizures | 47 (16.8) | 10 (1.1) | 19 (1.7) | <.01 | <.01 |
| Clinical findings | |||||
| Chest indrawing | 149/276 (54.0) | 542/925 (58.6) | 587/1135 (51.7) | .17 | .50 |
| Tachypnea | 144/270 (53.3) | 546/875 (62.4) | 569/1083 (52.5) | .01 | .82 |
| Hypoxia | 138/278 (49.6) | 334/926 (36.1) | 424/1136 (37.3) | <.01 | <.01 |
| Altered mental status | 26/266 (9.8) | 22/924 (2.4) | 10/1129 (0.9) | <.01 | <.01 |
| Hypotension | 9/280 (3.2) | 8/931 (0.9) | 9/1133 (0.8) | <.01 | <.01 |
| Illness onset to hospital admission, d (median, IQR) | 3 (1-6) | 3 (1-5) | 4 (2-6) | .58 | <.01 |
NA, not applicable.
Other condition includes chronic kidney disease, diabetes mellitus, chronic liver disease, and history of splenectomy.
Based on verified vaccine information. For all 3 vaccines, vaccination is considered received if given ≥2 wk prior to admission. For H influenzae type B vaccine, this was based on 1459/1469 (99%) children ≥19 mo for whom information was available; vaccinated was defined as having received ≥3 doses H influenzae type B vaccine. For pneumococcal conjugate vaccine, this was based on 1272/1280 (99%) of children 19 mo to 12 y for whom information was available; vaccinated was defined as having received ≥3 pneumococcal vaccine doses. For influenza vaccine, this was based on 2053/2084 (99%) children ≥6 mo for whom information was available; vaccinated was defined as having received ≥1 influenza vaccine dose during season. An influenza season was defined as September 1 to August 31 of the concurrent year.
Tachypnea is defined as ≥60 breaths per min in infants <2 mo; ≥50 breaths per min in infants ≥2 mo to <12 mo; ≥40 breaths per min in children ≥1 y to <5 y; and ≥25 breaths per min in ≥5 y to <18 y.
Hypoxia is defined as an oxygen saturation <92% on presentation or the receipt of any supplemental oxygen on presentation.
Hypotension is defined as a systolic blood pressure <60 mm Hg in infants <1 mo; <70 mm Hg in infants ≥1 mo to <1 y; <70 mm Hg + (2 mm Hg * age in y) in children ≥1 y to <10 y; and <90 in children ≥10 y.
Detection of pathogens∗ among children hospitalized with CAP comparing children with and without neurologic disorders among those with samples available for pathogen detection
| Microbiologic organisms | Group 1 | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Any neurologic disorder (n = 261) No. (%) | Non-neurologic underlying condition (n = 886) No. (%) | No underlying condition (n = 1075) No. (%) | Group 1 vs 2 | Group 1 vs 3 | |
| Any pathogen detection | 181 (69.4) | 748 (84.4) | 875 (81.4) | <.01 | <.01 |
| Single viral detection | 108 (41.4) | 455 (51.4) | 448 (41.7) | <.01 | .93 |
| Viral-viral co-detection | 38 (14.6) | 195 (22.0) | 228 (21.2) | <.01 | .02 |
| Single bacterial detection | 21 (8.0) | 43 (4.9) | 99 (9.2) | .05 | .06 |
| Bacterial-viral co-detection | 14 (5.4) | 48 (5.4) | 93 (8.7) | .97 | .08 |
| Bacterial-bacterial co-detection | 0 (0) | 7 (0.8) | 5 (0.5) | NA | NA |
| Specific viral detections | |||||
| Human rhinovirus | 63/254 (24.8) | 309/871 (35.5) | 234/1054 (22.2) | <.01 | .37 |
| RSV | 46 (17.6) | 246 (27.8) | 330 (30.7) | <.01 | <.01 |
| Human metapneumovirus | 40 (15.3) | 107 (12.1) | 138 (12.8) | .17 | .29 |
| Parainfluenza 1, 2, 3 viruses | 15 (5.8) | 49 (5.5) | 87 (8.1) | .89 | .20 |
| Adenovirus | 14 (5.4) | 114 (12.9) | 120 (11.2) | <.01 | <.01 |
| Influenza A/B viruses | 14 (5.4) | 54 (6.1) | 81 (7.5) | .66 | .22 |
| Coronaviruses | 11/254 (4.3) | 52/871 (6.0) | 47/1054 (4.5) | .32 | .93 |
| Specific bacterial detections | |||||
| | 24/254 (9.5) | 58/871 (6.7) | 96/1054 (9.1) | .13 | .87 |
| | 5 (1.9) | 19 (2.1) | 55 (5.1) | .82 | .03 |
| Viridans | 2/248 (0.8) | 5/825 (0.6) | 7/1026 (0.7) | .67 | .69 |
| | 1 (0.4) | 5 (0.6) | 10 (0.9) | 1.00 | .70 |
| | 1/254 (0.4) | 5/871 (0.6) | 6/1054 (0.6) | 1.00 | 1.00 |
| | 1/248 (0.4) | 2/825 (0.2) | 6/1026 (0.6) | NA | NA |
| Methicillin-susceptible | 1/248 (0.4) | 2/825 (0.2) | 2/1026 (0.2) | NA | NA |
| Methicillin-resistant | 0/248 (0) | 3/825 (0.4) | 14/1026 (1.4) | NA | NA |
| Other Gram-negative organisms | 0/248 (0) | 4/825 (0.5) | 5/1026 (0.5) | NA | NA |
PCR, polymerase chain reaction.
Results reflect pathogen detection based on sampling and pathogen definitions previously described. Proper sampling methodology was defined for bacterial detections as blood culture or whole blood PCR or pleural fluid culture or PCR or endotracheal aspirate culture or bronchoalveolar lavage culture results and for viral detections as a nasopharyngeal/oropharyngeal swab PCR or viral serology results.
Histoplasma capsulatum was detected in 2 patients.
Includes coronaviruses 229E, HKU1, NL63, and OC43.
Detection of pathogens∗,† among children hospitalized with CAP stratified by age in children with and without neurologic disorders among those with samples available for pathogen detection
| Microbiologic organisms | Group 1 | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Any neurologic disorder, No. (%) | Non-neurologic underlying condition, No. (%) | No underlying condition, No. (%) | Group 1 vs 2 | Group 1 vs 3 | |
| Any pathogen detection | |||||
| <2 y | 53/71 (74.7) | 327/366 (89.3) | 482/543 (88.8) | <.01 | <.01 |
| 2-4 y | 50/66 (75.8) | 201/232 (86.6) | 216/261 (82.8) | .03 | .19 |
| 5-17 y | 78/124 (62.9) | 220/288 (76.4) | 177/271 (65.3) | <.01 | .64 |
| Specific viral detections | |||||
| Human rhinovirus | |||||
| <2 y | 23/69 (33.3) | 118/361 (32.7) | 146/533 (27.4) | 1.0 | .30 |
| 2-4 y | 16/65 (24.6) | 74/228 (32.5) | 52/258 (20.2) | .29 | .43 |
| 5-17 y | 24/120 (20.0) | 117/282 (41.5) | 36/263 (13.7) | <.01 | .12 |
| RSV | |||||
| <2 y | 19/71 (26.8) | 146/366 (39.9) | 242/543 (44.6) | .04 | <.01 |
| 2-4 y | 15/66 (22.7) | 77/232 (33.2) | 72/261 (27.6) | .10 | .42 |
| 5-17 y | 12/124 (9.7) | 23/288 (8.0) | 16/271 (5.9) | .57 | .18 |
| Human metapneumovirus | |||||
| <2 y | 14/71 (19.7) | 48/366 (13.1) | 79/543 (14.6) | .14 | .25 |
| 2-4 y | 12/66 (18.2) | 41/232 (17.7) | 40/261 (15.3) | .92 | .57 |
| 5-17 y | 14/124 (11.3) | 18/288 (6.3) | 19/271 (7.0) | .08 | .15 |
| Parainfluenza 1, 2, 3 viruses | |||||
| <2 y | 2/71 (2.8) | 22/366 (6.0) | 48/543 (8.8) | .40 | .08 |
| 2-4 y | 5/66 (7.6) | 13/232 (5.6) | 25/261 (9.6) | .56 | .61 |
| 5-17 y | 8/124 (6.5) | 14/288 (4.9) | 14/271 (5.2) | .51 | .61 |
| Adenovirus | |||||
| <2 y | 5/71 (7.0) | 81/366 (22.1) | 90/543 (16.6) | <.01 | .04 |
| 2-4 y | 5/66 (7.6) | 24/232 (10.3) | 23/261 (8.8) | .50 | .75 |
| 5-17 y | 4/124 (3.2) | 9/288 (3.1) | 7/271 (2.6) | 1.0 | .75 |
| Influenza A/B viruses | |||||
| <2 y | 1/71 (1.4) | 16/366 (4.4) | 39/543 (7.2) | .33 | .07 |
| 2-4 y | 5/66 (7.6) | 12/232 (5.2) | 12/261 (4.6) | .55 | .35 |
| 5-17 y | 8/124 (6.5) | 26/288 (9.0) | 30/271 (11.1) | .38 | .15 |
| Coronaviruses | |||||
| <2 y | 3/69 (4.4) | 24/361 (6.7) | 27/533 (5.1) | .60 | 1.0 |
| 2-4 y | 3/65 (4.6) | 17/228 (7.5) | 13/258 (5.0) | .58 | 1.0 |
| 5-17 y | 5/120 (4.2) | 11/282 (3.9) | 7/263 (2.7) | 1.0 | .53 |
| Specific bacterial detections | |||||
| | |||||
| <2 y | 0/69 (0) | 12/361 (3.3) | 8/533 (1.5) | .23 | .61 |
| 2-4 y | 2/65 (3.1) | 7/228 (3.1) | 20/258 (7.8) | 1.0 | .27 |
| 5-17 y | 22/120 (18.3) | 39/282 (13.8) | 68/263 (25.9) | .25 | .11 |
| | |||||
| <2 y | 1/71 (1.4) | 11/366 (3.0) | 20/543 (3.7) | .70 | .49 |
| 2-4 y | 0/66 (0) | 4/232 (1.7) | 19/261 (7.3) | .58 | .02 |
| 5-17 y | 4/124 (3.2) | 4/288 (1.4) | 16/271 (5.9) | .25 | .26 |
| Viridans | |||||
| <2 y | 0/68 (0) | 3/348 (0.9) | 5/525 (1.0) | 1.0 | 1.0 |
| 2-4 y | 1/63 (1.6) | 1/212 (0.5) | 1/250 (0.4) | .41 | .36 |
| 5-17 y | 1/117 (0.9) | 1/265 (0.4) | 1/251 (0.4) | .52 | .54 |
| | |||||
| <2 y | 0/71 (0) | 3/366 (0.8) | 5/543 (0.9) | 1.0 | 1.0 |
| 2-4 y | 0/66 (0) | 1/232 (0.4) | 4/261 (1.5) | 1.0 | .59 |
| 5-17 y | 1/124 (0.8) | 1/288 (0.4) | 1/271 (0.4) | .51 | .53 |
| | |||||
| <2 y | 0/69 (0) | 2/361 (0.6) | 1/533 (0.2) | 1.0 | 1.0 |
| 2-4 y | 1/65 (1.5) | 1/228 (0.4) | 2/258 (0.8) | .40 | .49 |
| 5-17 y | 0/120 (0) | 2/282 (0.7) | 3/263 (1.1) | 1.0 | .56 |
| | |||||
| <2 y | 0/68 (0) | 2/348 (0.6) | 6/525 (1.1) | 1.0 | 1.0 |
| 2-4 y | 1/63 (1.6) | 0/212 (0) | 0/250 (0) | .23 | .20 |
| 5-17 y | 0/117 (0) | 0/265 (0) | 0/251 (0) | 1.0 | 1.0 |
| Methicillin-susceptible | |||||
| <2 y | 0/68 (0) | 1/348 (0.3) | 0/525 (0) | 1.0 | 1.0 |
| 2-4 y | 0/63 (0) | 0/212 (0) | 1/250 (0.4) | 1.0 | 1.0 |
| 5-17 y | 1/117 (0.9) | 1/265 (0.4) | 1/251 (0.4) | .52 | .54 |
| Methicillin-resistant | |||||
| <2 y | 0/68 (0) | 2/348 (0.6) | 7/525 (1.3) | 1.0 | 1.0 |
| 2-4 y | 0/63 (0) | 1/212 (0.5) | 3/250 (1.2) | 1.0 | 1.0 |
| 5-17 y | 0/117 (0) | 0/265 (0) | 4/251 (1.6) | 1.0 | .31 |
PCR, polymerase chain reaction.
Results reflect pathogen detection based on sampling and pathogen definitions previously described. Proper sampling methodology was defined for bacterial detections as blood culture or whole blood PCR or pleural fluid culture or PCR or endotracheal aspirate culture or bronchoalveolar lavage culture results and for viral detections as a nasopharyngeal/oropharyngeal swab PCR or viral serology results.
Histoplasma capsulatum was detected in 2 patients.
Includes coronaviruses 229E, HKU1, NL63, and OC43.
Clinical outcomes among children hospitalized with CAP with and without neurologic disorders
| Outcomes | Group 1 | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Neurologic disorder (n = 280) No. (%) | Non-neurologic underlying condition (n = 934) No. (%) | No underlying condition (n = 1144) No. (%) | Group 1 vs 2 | Group 1 vs 3 | |
| Hospital LOS (d, median, IQR) | 4 (2-7) | 3 (2-4) | 4 (2-4) | <.01 | <.01 |
| Hospital LOS >3 d | 154 (55.0) | 304 (32.6) | 368 (32.2) | <.01 | <.01 |
| ICU admission | 102 (36.4) | 185 (19.8) | 210 (18.4) | <.01 | <.01 |
| ICU LOS (d, median, IQR) | 3 (2-7) | 2 (1-5) | 2 (1-5) | .04 | .04 |
| ICU LOS >3 d | 49/102 (48.0) | 66/185 (35.7) | 86/210 (41.0) | .04 | .24 |
| Invasive mechanical ventilation | 34/102 (33.3) | 52/185 (28.1) | 80/210 (38.1) | .36 | .41 |
| Ventilator (d, median, IQR) | 3 (1-8) | 4 (1-8) | 4 (2-7) | .79 | .52 |
| Ventilator >4 d | 13/34 (38.2) | 25/52 (48.1) | 36/80 (45.0) | .10 | .22 |
| Documented receipt of vasopressors within 72 h of ICU admission | 7/102 (6.9%) | 10/185 (5.4%) | 20/210 (9.5) | .62 | .43 |
| Death | 1 (0.4) | 0 (0) | 2 (0.2) | NA | NA |
Characteristics of children hospitalized with CAP with and without neurologic disorders admitted to the ICU
| Characteristics | Group 1 | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Any neurologic disorder (n = 102) No. (%) | Non-neurologic underlying condition (n = 185) No. (%) | No underlying condition (n = 210) No. (%) | Group 1 vs 2 | Group 1 vs 3 | |
| Male | 55 (53.9) | 110 (59.5) | 114 (54.3) | .36 | .95 |
| Race/ethnicity | |||||
| Non-Hispanic white | 46 (45.1) | 74 (40.0) | 97 (46.2) | .40 | .86 |
| Non-Hispanic black | 29 (28.4) | 66 (35.7) | 32 (15.2) | .21 | <.01 |
| Hispanic | 20 (19.6) | 30 (16.2) | 59 (28.1) | .47 | .05 |
| Other | 7 (6.9) | 15 (8.1) | 22 (10.5) | .87 | .30 |
| Age groups | |||||
| <2 y | 27 (26.5) | 87 (47.0) | 140 (66.7) | <.01 | <.01 |
| 2-4 y | 23 (22.6) | 43 (23.2) | 37 (17.6) | .67 | .30 |
| 5-17 y | 52 (51.0) | 55 (29.7) | 33 (15.7) | <.01 | <.01 |
| Non-neurologic underlying condition | |||||
| Any non-neurologic underlying condition | 53 (52.0) | 185 (100) | NA | ||
| Congenital heart Disease | 39 (38.2) | 17 (9.2) | NA | <.01 | NA |
| Asthma/RAD | 30 (29.4) | 130 (70.3) | NA | <.01 | NA |
| Chronic lung disease | 15 (14.7) | 20 (10.8) | NA | .33 | NA |
| Pre-term birth (<37 wk) | 8/27 (29.6) | 46/87 (52.9) | NA | .03 | NA |
| Immunosuppressive condition | 2 (2.0) | 5 (2.7) | NA | 1.0 | NA |
| Other condition | 1 (1.0) | 8 (4.3) | NA | .12 | NA |
| Reported symptoms | |||||
| Cough | 90 (88.2) | 174 (94.1) | 193 (91.9) | .08 | .30 |
| Fever | 85 (83.3) | 161 (87.0) | 187 (89.1) | .39 | .16 |
| Shortness of breath | 79 (77.5) | 153 (82.7) | 156 (74.3) | .28 | .54 |
| Vomiting/nausea | 26 (25.5) | 97 (52.4) | 117 (55.7) | <.01 | <.01 |
| Altered mental status | 34 (33.3) | 46 (24.9) | 60 (28.6) | .13 | .39 |
| Diarrhea | 26 (25.5) | 39 (21.1) | 65 (31.0) | .39 | .32 |
| Seizures | 17 (16.7) | 3 (1.6) | 5 (2.4) | <.01 | <.01 |
| Clinical findings | |||||
| Chest indrawing | 67/101 (66.3) | 159/184 (86.4) | 155/208 (74.5) | <.01 | .13 |
| Tachypnea | 65/99 (65.7) | 121/178 (68.0) | 118/197 (59.9) | .69 | .34 |
| Hypoxia | 68/101 (67.3) | 111/185 (60.0) | 131/210 (62.4) | .22 | .39 |
| Altered mental status | 15/93 (16.1) | 15/180 (8.3) | 7/202 (3.5) | .05 | <.01 |
| Hypotension | 7/102 (6.9) | 5/183 (2.7) | 5/208 (2.4) | .12 | .07 |
| Illness onset to hospital admission, d (median, IQR) | 2 (1-5) | 2 (1-4) | 3 (2-5) | .98 | .09 |
NA, not applicable.
Other condition includes chronic kidney disease, diabetes mellitus, chronic liver disease, and history of splenectomy.
Tachypnea is defined as ≥60 breaths per min in infants <2 mo; ≥50 breaths per min in infants ≥2 mo to <12 mo; ≥40 breaths per min in children ≥1 y to <5 y; and ≥25 breaths per min in ≥5 y to <18 y.
Hypoxia is defined as an oxygen saturation <92% on presentation or the receipt of any supplemental oxygen on presentation.
Hypotension is defined as a systolic blood pressure <60 mm Hg in infants <1 mo; <70 mm Hg in infants ≥1 mo to <1 y; <70 mm Hg + (2 mm Hg * age in y) in children ≥1 y to <10 y; and <90 in children ≥10 y.
Subgroup analysis of clinical outcomes among children hospitalized with CAP with neurologic disorders with no other non-neurologic underlying conditions compared with children without neurologic disorders
| Outcomes | Group 1A | Group 2 | Group 3 | ||
|---|---|---|---|---|---|
| Neurologic disorder and no other underlying condition, n = 134 | Non-neurologic underlying condition, n = 934 | No underlying condition, n = 1144 | Group 1A vs 2 | Group 1A vs 3 | |
| Hospital LOS >3 d | 70 (52.2) | 304 (33.6) | 368 (32.2) | <.01 | <.01 |
| ICU admission | 49 (36.6) | 185 (19) | 210 (18.4) | <.01 | <.01 |
| ICU LOS >3 d | 23/49 (46.9) | 66/185 (35) | 80/210 (41) | .15 | .44 |
| Invasive mechanical ventilation | 21/49 (42.9) | 52/185 (28) | 80/210 (38.1) | .05 | .54 |
| Ventilator LOS >4 d | 7/21 (33.3) | 25/52 (48.1) | 36/80 (45.0) | .25 | .34 |
Age-stratified multivariate models of select clinical characteristics among children hospitalized with CAP with ICU admission as the outcome
| Clinical characteristics | aOR (95%) CI | ||
|---|---|---|---|
| Age <2 y (n = 963) | Age 2-4 y (n = 523) | Age 5-17 y (n = 687) | |
| Neurologic disorder | 1.0 (0.5-1.8) | 2.8 (1.4-5.5) | 3.6 (2.2-5.9) |
| Asthma/RAD | NA | 1.9 (1.2-3.0) | 1.4 (0.9-2.1) |
| Congenital heart disease | 1.5 (0.8-2.8) | 0.9 (0.4-2.3) | 1.0 (0.5-2.1) |
| Chronic lung disease | 2.3 (1.1-4.7) | 2.0 (0.8-4.6) | 0.8 (0.3-2.6) |
| Hypoxia | 2.9 (2.2-4.0) | 3.6 (2.2-5.8) | 4.2 (2.7-6.4) |
| Tachypnea | 0.9 (0.7-1.3) | 1.9 (1.1-3.1) | 2.0 (1.2-3.2) |
Asthma/RAD excluded from the <2 year age group because of the uncertainty of accurate diagnosis at that age.
Hypoxia is defined as an oxygen saturation <92% on presentation or the receipt of any supplemental oxygen on presentation.
Tachypnea is defined as ≥60 breaths per min in infants <2 mo; ≥50 breaths per min in infants ≥2 mo to <12 mo; ≥40 breaths per min in children ≥1 y to <5 y; and ≥25 breaths per minute in ≥5 y to <18 y.